XBiotech (XBIT) Other Non-Current Liabilities (2019 - 2026)
XBiotech (XBIT) posted quarterly Other Non-Current Liabilities of $1.8 million for Q4 2025, up 4.53% year-over-year from $1.7 million in Q4 2024, and up 1.07% quarter-over-quarter from $1.8 million in Q3 2025.
XBiotech (XBIT) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
XBiotech's Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $1.8 million for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities rose 4.53% year-over-year to $1.8 million; the TTM figure through Dec 2025 stood at $1.8 million (up 4.53% YoY), while the FY2025 annual figure was $1.8 million, up 4.53% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $1.8 million, up from $1.8 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $1.8 million in Q4 2025, with the low at $1.1 million in Q1 2021.
- The 5-year median for Other Non-Current Liabilities is $1.6 million (2023), against an average of $1.6 million.
- The sharpest annual moves came in 2021 and 2025: Other Non-Current Liabilities soared 31.91% in 2021, then increased 2.01% in 2025.
- XBiotech's Other Non-Current Liabilities stood at $1.5 million in 2021, then climbed by 7.5% to $1.6 million in 2022, then climbed by 5.9% to $1.7 million in 2023, then increased by 3.06% to $1.7 million in 2024, then rose by 4.53% to $1.8 million in 2025.
- Business Quant data shows XBIT's Other Non-Current Liabilities at $1.8 million in Q4 2025, $1.8 million in Q3 2025, and $1.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | XBiotech | 68.90 Mn | 68.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.83 Mn |
| Dec 31, 2025 | 1.80 Mn |
| Sep 30, 2025 | 1.78 Mn |
| Jun 30, 2025 | 1.76 Mn |
| Mar 31, 2025 | 1.74 Mn |
| Dec 31, 2024 | 1.72 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 1.72 Mn |
| Mar 31, 2024 | 1.69 Mn |
| Dec 31, 2023 | 1.67 Mn |
| Sep 30, 2023 | 1.65 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 1.60 Mn |
| Dec 31, 2022 | 1.58 Mn |
| Sep 30, 2022 | 1.58 Mn |
| Jun 30, 2022 | 1.56 Mn |
| Dec 31, 2021 | 1.47 Mn |
| Sep 30, 2021 | 1.39 Mn |
| Jun 30, 2021 | 1.39 Mn |
| Mar 31, 2021 | 1.12 Mn |